Cargando…

Investigation of Metal-Organic Framework-5 (MOF-5) as an Antitumor Drug Oridonin Sustained Release Carrier

Oridonin (ORI) is a natural active ingredient with strong anticancer activity. But its clinical use is restricted due to its poor water solubility, short half-life, and low bioavailability. The aim of this study is to utilize the metal organic framework material MOF-5 to load ORI in order to improve...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Gongsen, Luo, Juyuan, Cai, Mengru, Qin, Liuying, Wang, Yibo, Gao, Lili, Huang, Pingqing, Yu, Yingchao, Ding, Yangming, Dong, Xiaoxv, Yin, Xingbin, Ni, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767262/
https://www.ncbi.nlm.nih.gov/pubmed/31527488
http://dx.doi.org/10.3390/molecules24183369
_version_ 1783454876673507328
author Chen, Gongsen
Luo, Juyuan
Cai, Mengru
Qin, Liuying
Wang, Yibo
Gao, Lili
Huang, Pingqing
Yu, Yingchao
Ding, Yangming
Dong, Xiaoxv
Yin, Xingbin
Ni, Jian
author_facet Chen, Gongsen
Luo, Juyuan
Cai, Mengru
Qin, Liuying
Wang, Yibo
Gao, Lili
Huang, Pingqing
Yu, Yingchao
Ding, Yangming
Dong, Xiaoxv
Yin, Xingbin
Ni, Jian
author_sort Chen, Gongsen
collection PubMed
description Oridonin (ORI) is a natural active ingredient with strong anticancer activity. But its clinical use is restricted due to its poor water solubility, short half-life, and low bioavailability. The aim of this study is to utilize the metal organic framework material MOF-5 to load ORI in order to improve its release characteristics and bioavailability. Herein, MOF-5 was synthesized by the solvothermal method and direct addition method, and characterized by Scanning Electron Microscopy (SEM), X-Ray Diffraction (XRD), Fourier Transform Infrared Spectrometer (FTIR), Thermogravimetric Analysis (TG), Brunauer–Emmett–Teller (BET), and Dynamic Light Scattering (DLS), respectively. MOF-5 prepared by the optimal synthesis method was selected for drug-loading and in vitro release experiments. HepG2 cells were model cells. MTT assay, 4′,6-diamidino-2-phenylindole (DAPI) staining and Annexin V/PI assay were used to detect the biological safety of blank carriers and the anticancer activity of drug-loaded materials. The results showed that nano-MOF-5 prepared by the direct addition method had complete structure, uniform size and good biocompatibility, and was suitable as an ORI carrier. The drug loading of ORI@MOF-5 was 52.86% ± 0.59%. The sustained release effect was reliable, and the cumulative release rate was about 87% in 60 h. ORI@MOF-5 had significant cytotoxicity (IC50:22.99 μg/mL) and apoptosis effect on HepG2 cells. ORI@MOF-5 is hopeful to become a new anticancer sustained release preparation. MOF-5 has significant potential as a drug carrier material.
format Online
Article
Text
id pubmed-6767262
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67672622019-10-02 Investigation of Metal-Organic Framework-5 (MOF-5) as an Antitumor Drug Oridonin Sustained Release Carrier Chen, Gongsen Luo, Juyuan Cai, Mengru Qin, Liuying Wang, Yibo Gao, Lili Huang, Pingqing Yu, Yingchao Ding, Yangming Dong, Xiaoxv Yin, Xingbin Ni, Jian Molecules Article Oridonin (ORI) is a natural active ingredient with strong anticancer activity. But its clinical use is restricted due to its poor water solubility, short half-life, and low bioavailability. The aim of this study is to utilize the metal organic framework material MOF-5 to load ORI in order to improve its release characteristics and bioavailability. Herein, MOF-5 was synthesized by the solvothermal method and direct addition method, and characterized by Scanning Electron Microscopy (SEM), X-Ray Diffraction (XRD), Fourier Transform Infrared Spectrometer (FTIR), Thermogravimetric Analysis (TG), Brunauer–Emmett–Teller (BET), and Dynamic Light Scattering (DLS), respectively. MOF-5 prepared by the optimal synthesis method was selected for drug-loading and in vitro release experiments. HepG2 cells were model cells. MTT assay, 4′,6-diamidino-2-phenylindole (DAPI) staining and Annexin V/PI assay were used to detect the biological safety of blank carriers and the anticancer activity of drug-loaded materials. The results showed that nano-MOF-5 prepared by the direct addition method had complete structure, uniform size and good biocompatibility, and was suitable as an ORI carrier. The drug loading of ORI@MOF-5 was 52.86% ± 0.59%. The sustained release effect was reliable, and the cumulative release rate was about 87% in 60 h. ORI@MOF-5 had significant cytotoxicity (IC50:22.99 μg/mL) and apoptosis effect on HepG2 cells. ORI@MOF-5 is hopeful to become a new anticancer sustained release preparation. MOF-5 has significant potential as a drug carrier material. MDPI 2019-09-16 /pmc/articles/PMC6767262/ /pubmed/31527488 http://dx.doi.org/10.3390/molecules24183369 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chen, Gongsen
Luo, Juyuan
Cai, Mengru
Qin, Liuying
Wang, Yibo
Gao, Lili
Huang, Pingqing
Yu, Yingchao
Ding, Yangming
Dong, Xiaoxv
Yin, Xingbin
Ni, Jian
Investigation of Metal-Organic Framework-5 (MOF-5) as an Antitumor Drug Oridonin Sustained Release Carrier
title Investigation of Metal-Organic Framework-5 (MOF-5) as an Antitumor Drug Oridonin Sustained Release Carrier
title_full Investigation of Metal-Organic Framework-5 (MOF-5) as an Antitumor Drug Oridonin Sustained Release Carrier
title_fullStr Investigation of Metal-Organic Framework-5 (MOF-5) as an Antitumor Drug Oridonin Sustained Release Carrier
title_full_unstemmed Investigation of Metal-Organic Framework-5 (MOF-5) as an Antitumor Drug Oridonin Sustained Release Carrier
title_short Investigation of Metal-Organic Framework-5 (MOF-5) as an Antitumor Drug Oridonin Sustained Release Carrier
title_sort investigation of metal-organic framework-5 (mof-5) as an antitumor drug oridonin sustained release carrier
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767262/
https://www.ncbi.nlm.nih.gov/pubmed/31527488
http://dx.doi.org/10.3390/molecules24183369
work_keys_str_mv AT chengongsen investigationofmetalorganicframework5mof5asanantitumordrugoridoninsustainedreleasecarrier
AT luojuyuan investigationofmetalorganicframework5mof5asanantitumordrugoridoninsustainedreleasecarrier
AT caimengru investigationofmetalorganicframework5mof5asanantitumordrugoridoninsustainedreleasecarrier
AT qinliuying investigationofmetalorganicframework5mof5asanantitumordrugoridoninsustainedreleasecarrier
AT wangyibo investigationofmetalorganicframework5mof5asanantitumordrugoridoninsustainedreleasecarrier
AT gaolili investigationofmetalorganicframework5mof5asanantitumordrugoridoninsustainedreleasecarrier
AT huangpingqing investigationofmetalorganicframework5mof5asanantitumordrugoridoninsustainedreleasecarrier
AT yuyingchao investigationofmetalorganicframework5mof5asanantitumordrugoridoninsustainedreleasecarrier
AT dingyangming investigationofmetalorganicframework5mof5asanantitumordrugoridoninsustainedreleasecarrier
AT dongxiaoxv investigationofmetalorganicframework5mof5asanantitumordrugoridoninsustainedreleasecarrier
AT yinxingbin investigationofmetalorganicframework5mof5asanantitumordrugoridoninsustainedreleasecarrier
AT nijian investigationofmetalorganicframework5mof5asanantitumordrugoridoninsustainedreleasecarrier